1. In Vivo

Exeliom’s Bacteria-Focused Approach To Immunotherapy

 
• By Janelle Hart

In Vivo sat down with Benjamin Hadida, CEO of Exeliom, at the 2024 BIO International Convention to discuss how the company is using its first-in-class drug candidate to improve therapeutic responsiveness in immuno-oncology, immuno-inflammation and rare disease. 

Three parallel trials drive forward a Bacteria-Focused approach to Immunotherapy • Source: Shutterstock

France-based Exeliom Biosciences is developing EXL01, a first-in-class drug candidate that uses gut bacteria sourced from the microbiome to produce impactful immunotherapies across indications.

While the science behind Exeliom was developed by three researchers – Harry Sokol, a professor in gastroenterology, Patrick Gervais, a professor in process engineering and Philippe Langella, a microbiologist, who all previously worked in academia together – the biotech is led by

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By Jo Shorthouse

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By Jo Shorthouse

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Lighting The Way To Anxiety Treatments With No Side Effects

 
• By Ian Taylor

Cutting-edge research is revolutionizing anxiety treatment by targeting specific brain circuits, paving the way for therapies that are free from side effects. This innovative approach promises more efficient and precise medicine, offering hope to millions of people living with anxiety.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

More from In Vivo